Ivermectin: Evaluation of Efficacy and Safety in COVID-19
The search for an effective and safe COVID-19 therapy involves, among other things, assessment of efficacy of medicines already used for the treatment of other diseases, and having potential antiviral activity against SARS-CoV-2. The relevance of the presented study stems from ambiguous data on the...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2022-04-01
|
| Series: | Безопасность и риск фармакотерапии |
| Subjects: | |
| Online Access: | https://www.risksafety.ru/jour/article/view/277 |
| _version_ | 1797224584536129536 |
|---|---|
| author | E. V. Shubnikova N. A. Susekova T. M. Bukatina M. S. Galenko A. A. Druzhinina |
| author_facet | E. V. Shubnikova N. A. Susekova T. M. Bukatina M. S. Galenko A. A. Druzhinina |
| author_sort | E. V. Shubnikova |
| collection | DOAJ |
| description | The search for an effective and safe COVID-19 therapy involves, among other things, assessment of efficacy of medicines already used for the treatment of other diseases, and having potential antiviral activity against SARS-CoV-2. The relevance of the presented study stems from ambiguous data on the off-label use of the antiparasitic medicine ivermectin for the treatment of COVID-19 patients. The aim of the study was to analyse ivermectin efficacy and safety for COVID-19 treatment, as reflected in the scientific literature. Ivermectin, an antiparasitic medicine from the group of macrocyclic lactones produced by Streptomyces avermitilis, stimulates release of the inhibitory neurotransmitter gamma-aminobutyric acid, which leads to impaired transmission of nerve impulses, paralysis and death of parasites. The results of preclinical studies show ivermectin’s inhibitory activity against a number of RNA and DNA viruses, including SARS-CoV-2. The results of ivermectin clinical studies are ambiguous: a number of studies demonstrated a positive effect on the condition of COVID-19 patients, however, there is currently no convincing evidence of the validity and efficacy of ivermectin use for the prevention and treatment of COVID-19 patients. The safety profile of ivermectin is relatively favourable. Large randomised controlled trials are needed to fully assess the feasibility of using ivermectin in COVID-19. |
| first_indexed | 2024-03-08T22:27:04Z |
| format | Article |
| id | doaj.art-1b15e6f738d9463bab69713906de8cff |
| institution | Directory Open Access Journal |
| issn | 2312-7821 2619-1164 |
| language | Russian |
| last_indexed | 2024-04-24T13:55:27Z |
| publishDate | 2022-04-01 |
| publisher | Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» |
| record_format | Article |
| series | Безопасность и риск фармакотерапии |
| spelling | doaj.art-1b15e6f738d9463bab69713906de8cff2024-04-03T17:56:37ZrusMinistry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Безопасность и риск фармакотерапии2312-78212619-11642022-04-01101193310.30895/2312-7821-2022-10-1-19-33214Ivermectin: Evaluation of Efficacy and Safety in COVID-19E. V. Shubnikova0N. A. Susekova1T. M. Bukatina2M. S. Galenko3A. A. Druzhinina4Scientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal Products; I.M. Sechenov First Moscow State Medical University (Sechenov University)Scientific Centre for Expert Evaluation of Medicinal ProductsThe search for an effective and safe COVID-19 therapy involves, among other things, assessment of efficacy of medicines already used for the treatment of other diseases, and having potential antiviral activity against SARS-CoV-2. The relevance of the presented study stems from ambiguous data on the off-label use of the antiparasitic medicine ivermectin for the treatment of COVID-19 patients. The aim of the study was to analyse ivermectin efficacy and safety for COVID-19 treatment, as reflected in the scientific literature. Ivermectin, an antiparasitic medicine from the group of macrocyclic lactones produced by Streptomyces avermitilis, stimulates release of the inhibitory neurotransmitter gamma-aminobutyric acid, which leads to impaired transmission of nerve impulses, paralysis and death of parasites. The results of preclinical studies show ivermectin’s inhibitory activity against a number of RNA and DNA viruses, including SARS-CoV-2. The results of ivermectin clinical studies are ambiguous: a number of studies demonstrated a positive effect on the condition of COVID-19 patients, however, there is currently no convincing evidence of the validity and efficacy of ivermectin use for the prevention and treatment of COVID-19 patients. The safety profile of ivermectin is relatively favourable. Large randomised controlled trials are needed to fully assess the feasibility of using ivermectin in COVID-19.https://www.risksafety.ru/jour/article/view/277ivermectinsars-cov-2covid-19coronavirus infectionefficacysafetyadverse drug reactionscovid-19 treatment |
| spellingShingle | E. V. Shubnikova N. A. Susekova T. M. Bukatina M. S. Galenko A. A. Druzhinina Ivermectin: Evaluation of Efficacy and Safety in COVID-19 Безопасность и риск фармакотерапии ivermectin sars-cov-2 covid-19 coronavirus infection efficacy safety adverse drug reactions covid-19 treatment |
| title | Ivermectin: Evaluation of Efficacy and Safety in COVID-19 |
| title_full | Ivermectin: Evaluation of Efficacy and Safety in COVID-19 |
| title_fullStr | Ivermectin: Evaluation of Efficacy and Safety in COVID-19 |
| title_full_unstemmed | Ivermectin: Evaluation of Efficacy and Safety in COVID-19 |
| title_short | Ivermectin: Evaluation of Efficacy and Safety in COVID-19 |
| title_sort | ivermectin evaluation of efficacy and safety in covid 19 |
| topic | ivermectin sars-cov-2 covid-19 coronavirus infection efficacy safety adverse drug reactions covid-19 treatment |
| url | https://www.risksafety.ru/jour/article/view/277 |
| work_keys_str_mv | AT evshubnikova ivermectinevaluationofefficacyandsafetyincovid19 AT nasusekova ivermectinevaluationofefficacyandsafetyincovid19 AT tmbukatina ivermectinevaluationofefficacyandsafetyincovid19 AT msgalenko ivermectinevaluationofefficacyandsafetyincovid19 AT aadruzhinina ivermectinevaluationofefficacyandsafetyincovid19 |